<DOC>
	<DOCNO>NCT00615992</DOCNO>
	<brief_summary>The primary goal post marketing surveillance ( PMS ) study document efficacy Tiotropium ( Spiriva ) improve physical activity measure score recommend national chronic obstructive pulmonary disease ( COPD ) guideline monitor course disease .</brief_summary>
	<brief_title>Effect Spiriva Activities Daily Living Score Recommended Austrian COPD Guidelines</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients suspect chronic obstructive pulmonary disease ( COPD ) 3 positive answer COPD questionnaire Age 40 year Patients condition list special precaution , drug interaction , contraindication Spiriva summary product characteristic Patient treat Spiriva past year Patient history hypersensitivity tiotropium bromide , atropine and/or derivant , i.e . ipratropium , component Spiriva Patient know narrowangle glaucoma Patient know symptomatic prostatic hyperplasia and/or bladderneck obstruction Patient know moderate severe renal impairment ( i.e. , creatinine clearance &lt; =50ml/min ) Pregnant nurse woman Patient significant disease COPD would exclude him/her participate study Patients condition list special precaution , drug interaction , contraindication Spiriva Austrian summary product characteristic</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>